This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsVIOL (A335890) 주식 개요바이올(주)은 전기 진단 및 의료 기기를 제조하는 회사입니다. 자세히 보기A335890 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장5/6과거 실적0/6재무 건전성0/6배당0/6강점수익은 매년 22.62% 증가할 것으로 예상됩니다.위험 분석지난 3개월 동안 주가 변동성이 KR 시장과 비교했을 때 매우 높았습니다.모든 위험 점검 보기A335890 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW497,995 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG497,995 investors already sharing narrativesYour Fair Value₩Current Price₩12.50k251.4% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3b91b2016201920222025202620282031Revenue ₩90.6bEarnings ₩11.8bAdvancedSet Fair ValueView all narrativesVIOL Co., Ltd. 경쟁사Next BiomedicalLtdSymbol: KOSDAQ:A389650Market cap: ₩334.4bWON TECHLtdSymbol: KOSDAQ:A336570Market cap: ₩519.6bTomocubeSymbol: KOSDAQ:A475960Market cap: ₩445.0bASTERASYSLtdSymbol: KOSDAQ:A450950Market cap: ₩262.6b가격 이력 및 성과VIOL 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩12,500.0052주 최고가₩27,500.0052주 최저가₩6,380.00베타01개월 변동0%3개월 변동-0.16%1년 변동59.44%3년 변동321.59%5년 변동378.93%IPO 이후 변동521.89%최근 뉴스 및 업데이트Board Change • Dec 01Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Declared Dividend • Nov 08Dividend of ₩20.00 announcedDividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growth공시 • Nov 07VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Price Target Changed • Apr 04Price target decreased by 7.2% to ₩11,420Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.공시 • Mar 12VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea더 많은 업데이트 보기Recent updatesBoard Change • Dec 01Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Declared Dividend • Nov 08Dividend of ₩20.00 announcedDividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growth공시 • Nov 07VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Price Target Changed • Apr 04Price target decreased by 7.2% to ₩11,420Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.공시 • Mar 12VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South KoreaPrice Target Changed • Feb 04Price target decreased by 7.0% to ₩12,300Down from ₩13,229, the current price target is an average from 7 analysts. New target price is 56% above last closing price of ₩7,890. Stock is up 7.3% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.Price Target Changed • Dec 17Price target decreased by 7.0% to ₩12,586Down from ₩13,533, the current price target is an average from 7 analysts. New target price is 53% above last closing price of ₩8,200. Stock is down 1.1% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩8,070, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 235% over the past three years.Price Target Changed • May 12Price target increased by 10% to ₩12,000Up from ₩10,875, the current price target is an average from 4 analysts. New target price is 6.6% above last closing price of ₩11,260. Stock is up 82% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩11,260, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 360% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,197 per share.분석 기사 • May 09Here's Why We Think VIOL (KOSDAQ:335890) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Buy Or Sell Opportunity • Apr 02Now 28% undervaluedOver the last 90 days, the stock has risen 15% to ₩10,360. The fair value is estimated to be ₩14,309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 115% in the next 2 years.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩10,140, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 375% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,295 per share.New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩8,480, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,331 per share.분석 기사 • Mar 01Why The 37% Return On Capital At VIOL (KOSDAQ:335890) Should Have Your AttentionDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Upcoming Dividend • Dec 20Upcoming dividend of ₩10.00 per share at 0.1% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 23 April 2024. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).Buying Opportunity • Dec 05Now 21% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be ₩10,718, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 99% in 2 years. Earnings is forecast to grow by 116% in the next 2 years.Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,590, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 277% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,842 per share.New Risk • Nov 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change).New Risk • Nov 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.Buying Opportunity • Aug 09Now 20% undervaluedOver the last 90 days, the stock is up 34%. The fair value is estimated to be ₩10,563, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 116% in the next 2 years.Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩6,130, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩5,740, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 185% over the past three years.Buying Opportunity • Mar 23Now 20% undervaluedOver the last 90 days, the stock is up 63%. The fair value is estimated to be ₩5,713, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last year. Earnings per share has grown by 149%. Revenue is forecast to grow by 125% in 2 years. Earnings is forecast to grow by 143% in the next 2 years.Reported Earnings • Mar 18Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩198 (up from ₩80.00 in FY 2021). Revenue: ₩31.1b (up 69% from FY 2021). Net income: ₩11.5b (up 159% from FY 2021). Profit margin: 37% (up from 24% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 4.6%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Medical Equipment industry in South Korea.Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩5,150, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩4,730 per share.Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩3,780, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 88% over the past three years.Buying Opportunity • Nov 28Now 22% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be ₩3,332, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 139% in 2 years. Earnings is forecast to grow by 112% in the next 2 years.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₩68.00 (vs ₩19.00 in 3Q 2021)Third quarter 2022 results: EPS: ₩68.00 (up from ₩19.00 in 3Q 2021). Revenue: ₩7.61b (up 66% from 3Q 2021). Net income: ₩3.94b (up 267% from 3Q 2021). Profit margin: 52% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Medical Equipment industry in South Korea.공시 • Nov 11VIOL Co., Ltd. (KOSDAQ:A335890) announces an Equity Buyback for KRW 3,000 million worth of its shares.VIOL Co., Ltd. (KOSDAQ:A335890) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with KB Securities co.Ltd. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on May 13, 2023. As of November 10, 2022, the company had no shares within scope available for dividend and had 21 shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩1,990, the stock trades at a trailing P/E ratio of 14.5x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.2% over the past year.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩1,730, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 30% over the past year.Is New 90 Day High Low • Mar 09New 90-day low: ₩2,180The company is down 12% from its price of ₩2,475 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period.공시 • Nov 13Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction.Viol Co., Ltd. agreed to acquire IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on May 11, 2020. Under the terms of transaction the merger ratio is 1: 136.682. As per the amendments on September 7, 2020, the merger ratio was changed to 1: 124.875 (Ibks No.11 Spac Co., Ltd. : Viol Co., Ltd.). Post completion, DMS Co., Ltd., largest shareholder in Viol will own a 62.43% stake in the merged company. Through this merger, Viol Co., Ltd. will actually enjoy listing on the KOSDAQ market. The transaction is subject to approval of more than two-thirds of the voting rights of participating shareholders and one-third of the total number of shares issued in IBKS No.11. The transaction has been approved by the board of directors of IBKS No.11. The transaction is expected to close on October 12, 2020. As on July 16, 2020, the transaction is expected to close on November 2, 2020. As of September 7, 2020, the transaction was expected to close on November 11, 2020. Hanul Accounting Corporation acted as the accountant to IBKS No.11 Special Purpose Acquisition Company. Hyun Accounting Corporation acted as accountant to Viol Co., Ltd. Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on November 12, 2020.주주 수익률A335890KR Medical EquipmentKR 시장7D0%5.0%-3.6%1Y59.4%-14.7%148.4%전체 주주 수익률 보기수익률 대 산업: A335890은 지난 1년 동안 -14.7%의 수익을 기록한 KR Medical Equipment 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: A335890은 지난 1년 동안 148.4%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A335890's price volatile compared to industry and market?A335890 volatilityA335890 Average Weekly Movement21.2%Medical Equipment Industry Average Movement8.6%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%안정적인 주가: A335890의 주가는 지난 3개월 동안 KR 시장보다 변동성이 컸습니다.시간에 따른 변동성: A335890의 주간 변동성은 지난 1년간 10%에서 21%로 증가했습니다.회사 소개설립직원 수CEO웹사이트2007n/aLee Sang Jinwww.viol.co.kr/en바이올은 전기 진단 및 의료 기기를 제조하는 회사입니다. 이 회사는 2007년에 설립되었으며 대한민국 성남에 본사를 두고 있습니다.더 보기VIOL Co., Ltd. 기초 지표 요약VIOL의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A335890 기초 통계시가총액₩721.79b순이익 (TTM)₩14.29b매출 (TTM)₩35.49b0.0x주가수익비율(P/E)0.0x주가매출비율(P/S)A335890는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A335890 손익계산서 (TTM)매출₩35.49b매출원가₩8.87b총이익₩26.61b기타 비용₩12.32b순이익₩14.29b최근 보고된 실적Mar 31, 2023다음 실적 발표일해당 없음주당순이익(EPS)0총이익률0.00%순이익률0.00%부채/자본 비율0.0%A335890의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당0.2%현재 배당 수익률n/a배당 성향A335890는 안정적으로 배당을 지급합니까?A335890 배당 기록 및 벤치마크 보기다가오는 배당을 받으려면 언제까지 A335890를 매수해야 하나요?VIOL 배당 일정배당락일Dec 29 2025배당 지급일Apr 24 2026배당락일까지 남은 일수190 days배당 지급일까지 남은 일수74 daysA335890는 안정적으로 배당을 지급합니까?A335890 배당 기록 및 벤치마크 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/10 20:51종가2025/12/09 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스VIOL Co., Ltd.는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ji-Eun KimDB Financial Investment Co. Ltd.Yougun HanKB Securities Co., Ltd.Sion KangKorea Investment & Securities Co., Ltd.4명의 분석가 더 보기
Board Change • Dec 01Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Declared Dividend • Nov 08Dividend of ₩20.00 announcedDividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growth
공시 • Nov 07VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Price Target Changed • Apr 04Price target decreased by 7.2% to ₩11,420Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
공시 • Mar 12VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
Board Change • Dec 01Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Declared Dividend • Nov 08Dividend of ₩20.00 announcedDividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growth
공시 • Nov 07VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Price Target Changed • Apr 04Price target decreased by 7.2% to ₩11,420Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
공시 • Mar 12VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
Price Target Changed • Feb 04Price target decreased by 7.0% to ₩12,300Down from ₩13,229, the current price target is an average from 7 analysts. New target price is 56% above last closing price of ₩7,890. Stock is up 7.3% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
Price Target Changed • Dec 17Price target decreased by 7.0% to ₩12,586Down from ₩13,533, the current price target is an average from 7 analysts. New target price is 53% above last closing price of ₩8,200. Stock is down 1.1% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩8,070, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 235% over the past three years.
Price Target Changed • May 12Price target increased by 10% to ₩12,000Up from ₩10,875, the current price target is an average from 4 analysts. New target price is 6.6% above last closing price of ₩11,260. Stock is up 82% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩11,260, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 360% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,197 per share.
분석 기사 • May 09Here's Why We Think VIOL (KOSDAQ:335890) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Buy Or Sell Opportunity • Apr 02Now 28% undervaluedOver the last 90 days, the stock has risen 15% to ₩10,360. The fair value is estimated to be ₩14,309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 115% in the next 2 years.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩10,140, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 375% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,295 per share.
New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩8,480, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,331 per share.
분석 기사 • Mar 01Why The 37% Return On Capital At VIOL (KOSDAQ:335890) Should Have Your AttentionDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Dec 20Upcoming dividend of ₩10.00 per share at 0.1% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 23 April 2024. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).
Buying Opportunity • Dec 05Now 21% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be ₩10,718, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 99% in 2 years. Earnings is forecast to grow by 116% in the next 2 years.
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,590, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 277% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,842 per share.
New Risk • Nov 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change).
New Risk • Nov 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.
Buying Opportunity • Aug 09Now 20% undervaluedOver the last 90 days, the stock is up 34%. The fair value is estimated to be ₩10,563, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 116% in the next 2 years.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩6,130, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩5,740, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 185% over the past three years.
Buying Opportunity • Mar 23Now 20% undervaluedOver the last 90 days, the stock is up 63%. The fair value is estimated to be ₩5,713, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last year. Earnings per share has grown by 149%. Revenue is forecast to grow by 125% in 2 years. Earnings is forecast to grow by 143% in the next 2 years.
Reported Earnings • Mar 18Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩198 (up from ₩80.00 in FY 2021). Revenue: ₩31.1b (up 69% from FY 2021). Net income: ₩11.5b (up 159% from FY 2021). Profit margin: 37% (up from 24% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 4.6%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Medical Equipment industry in South Korea.
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩5,150, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩4,730 per share.
Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩3,780, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 88% over the past three years.
Buying Opportunity • Nov 28Now 22% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be ₩3,332, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 139% in 2 years. Earnings is forecast to grow by 112% in the next 2 years.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₩68.00 (vs ₩19.00 in 3Q 2021)Third quarter 2022 results: EPS: ₩68.00 (up from ₩19.00 in 3Q 2021). Revenue: ₩7.61b (up 66% from 3Q 2021). Net income: ₩3.94b (up 267% from 3Q 2021). Profit margin: 52% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Medical Equipment industry in South Korea.
공시 • Nov 11VIOL Co., Ltd. (KOSDAQ:A335890) announces an Equity Buyback for KRW 3,000 million worth of its shares.VIOL Co., Ltd. (KOSDAQ:A335890) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with KB Securities co.Ltd. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on May 13, 2023. As of November 10, 2022, the company had no shares within scope available for dividend and had 21 shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩1,990, the stock trades at a trailing P/E ratio of 14.5x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.2% over the past year.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩1,730, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 30% over the past year.
Is New 90 Day High Low • Mar 09New 90-day low: ₩2,180The company is down 12% from its price of ₩2,475 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period.
공시 • Nov 13Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction.Viol Co., Ltd. agreed to acquire IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on May 11, 2020. Under the terms of transaction the merger ratio is 1: 136.682. As per the amendments on September 7, 2020, the merger ratio was changed to 1: 124.875 (Ibks No.11 Spac Co., Ltd. : Viol Co., Ltd.). Post completion, DMS Co., Ltd., largest shareholder in Viol will own a 62.43% stake in the merged company. Through this merger, Viol Co., Ltd. will actually enjoy listing on the KOSDAQ market. The transaction is subject to approval of more than two-thirds of the voting rights of participating shareholders and one-third of the total number of shares issued in IBKS No.11. The transaction has been approved by the board of directors of IBKS No.11. The transaction is expected to close on October 12, 2020. As on July 16, 2020, the transaction is expected to close on November 2, 2020. As of September 7, 2020, the transaction was expected to close on November 11, 2020. Hanul Accounting Corporation acted as the accountant to IBKS No.11 Special Purpose Acquisition Company. Hyun Accounting Corporation acted as accountant to Viol Co., Ltd. Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on November 12, 2020.
